pharmaceutical investing Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs
Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
American Uranium's Lo Herma Resource Reaches 9.96Mlbs as Indicated Resources Grow 72% Prior to Publication of Planned Scoping Study
